Generic Ciprodex Availability

Ciprodex is a brand name of ciprofloxacin/dexamethasone otic, approved by the FDA in the following formulation(s):

CIPRODEX (ciprofloxacin; dexamethasone - suspension/drops;otic)

  • Manufacturer: ALCON PHARMS LTD
    Approval date: July 18, 2003
    Strength(s): 0.3%;0.1% [RLD]

Has a generic version of Ciprodex been approved?

No. There is currently no therapeutically equivalent version of Ciprodex available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ciprodex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Topical suspension formulations containing ciprofloxacin and dexamethasone
    Patent 6,284,804
    Issued: September 4, 2001
    Inventor(s): Singh; Onkar N. & Bhagat; Haresh G.
    Assignee(s): Alcon Universal Ltd.
    Suspension formulations containing dexamethasone and ciprofloxacin are disclosed. The formulations contain a nonionic polymer, a nonionic surfactant and an ionic tonicity agent, but are physically stable and easily re-suspended. The formulations are intended for topical application to the eye, ear or nose.
    Patent expiration dates:
    • August 10, 2020
  • Topical suspension formulations containing ciprofloxacin and dexamethasone
    Patent 6,359,016
    Issued: March 19, 2002
    Inventor(s): Onkar N.; Singh & Haresh G.; Bhagat
    Assignee(s): Alcon Universal Ltd.
    Suspension formulations containing dexamethasone and ciprofloxacin are disclosed. The formulations contain a nonionic polymer, a nonionic surfactant and an ionic tonicity agent, but are physically stable and easily re-suspended. The formulations are intended for topical application to the eye, ear or nose.
    Patent expiration dates:
    • August 10, 2020
  • Method of treating middle ear infections
    Patent 8,846,650
    Issued: September 30, 2014
    Assignee(s): Novartis AG
    Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.
    Patent expiration dates:
    • June 4, 2025
      ✓ 
      Patent use: TREATMENT OF ACUTE OTITIS MEDIA
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web5)